Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Patent Litigation Relates Mostly To Formulation, Use Patents, FTC Says

Executive Summary

A majority of drug patent challenges involve patents that do not cover the active ingredient, Federal Trade Commission Chairman Timothy Muris told a Senate Commerce Committee hearing on generic drugs April 23

You may also be interested in...



Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data

Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states

FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic

The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx

FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic

The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx

Related Content

UsernamePublicRestriction

Register

PS039756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel